Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis.
Unal Atas, Ozan Salim, Utku Iltar, Orhan Kemal Yucel, Ayse Hilal Kucukdiler Eroglu, Vedat Aslan, Murat Yildirim, Ozen Dedeoglu, Sema Secilmis, Turgay Ulas, Burak Deveci, Sedanur Karaman Gulsaran, Ayfer Geduk, Fatih Yaman, Ibrahim Ethem Pinar, Senem Maral, Ahmet Sarici, Serhat Celik, Hande Ogul, Sidika Gulkan Ozkan, Aliihsan Gemici, Ahmet Kursat Gunes, Anil Tombak, Irfan Yavasoglu, Volkan Karakus, Melda Comert, Tayfur Toptas, Mehmet Sinan Dal, Rabin Saba, Hakki Onur Kirgizlar, Ozgur Mehtap, Eren Gunduz, Fahir Ozkalemkas, Murat Albayrak, Ilhami Berber, Muzaffer Keklik, Nil Guler, Hasan Atilla Ozkan, Omur Gokmen Sevindik, Zahit Bolaman, Erdal Kurtoglu, Meltem Ayli, Tülin Firatli Tuglular, Fevzi Altuntas, Levent Undar
{"title":"Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis.","authors":"Unal Atas, Ozan Salim, Utku Iltar, Orhan Kemal Yucel, Ayse Hilal Kucukdiler Eroglu, Vedat Aslan, Murat Yildirim, Ozen Dedeoglu, Sema Secilmis, Turgay Ulas, Burak Deveci, Sedanur Karaman Gulsaran, Ayfer Geduk, Fatih Yaman, Ibrahim Ethem Pinar, Senem Maral, Ahmet Sarici, Serhat Celik, Hande Ogul, Sidika Gulkan Ozkan, Aliihsan Gemici, Ahmet Kursat Gunes, Anil Tombak, Irfan Yavasoglu, Volkan Karakus, Melda Comert, Tayfur Toptas, Mehmet Sinan Dal, Rabin Saba, Hakki Onur Kirgizlar, Ozgur Mehtap, Eren Gunduz, Fahir Ozkalemkas, Murat Albayrak, Ilhami Berber, Muzaffer Keklik, Nil Guler, Hasan Atilla Ozkan, Omur Gokmen Sevindik, Zahit Bolaman, Erdal Kurtoglu, Meltem Ayli, Tülin Firatli Tuglular, Fevzi Altuntas, Levent Undar","doi":"10.4274/tjh.galenos.2024.2024.0450","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>In this study, we aimed to obtain real-life data on the use of antimyeloma agents, which significantly increase overall survival (OS) in multiple myeloma (MM) patients, in primary plasma cell leukemia (pPCL) patients with a poor prognosis.</p><p><strong>Materials and methods: </strong>Data from 53 patients who were diagnosed with pPCL between 2011-2020 and who used at least one proteasome inhibitor (PI) and/or immunomodulatory (IMID) agent were analyzed retrospectively. Depending on the year of pPCL diagnosis, 20% leukocytes or ≥2×109/L plasma cells in the peripheral blood were used.</p><p><strong>Results: </strong>The median age of the patients was 58 years, and 23 (43.4%) patients were over 65 years of age. For first-line treatment, PI or IMID alone was used in 31 (58.5%) patients, and PI and IMID were used simultaneously in 15 (28.3%) patients. Additionally, 21 (39.6%) patients received transplantation, and 13 (24.5%) patients received maintenance treatment. The median progression-free survival was 4 (1-42) months. When patients whose primary disease was refractory to first-line therapy were excluded, the duration of treatment was 6.5 months. The median OS was 15 months, with a median follow-up of 15 months. Only 7 (13.2%) of the patients were alive at the last follow-up visit. Those with higher beta-2 microglobulin levels and ISS stage 3 and nontransplant patients receiving first-line treatment had shorter OS (p=0.005, p=0.02 and p=0.008, respectively). Otherwise, the concomitant use of PIs and IMIDs, the addition of chemotherapy to induction therapy, and the response to induction therapy or maintenance therapy did not affect OS.</p><p><strong>Conclusion: </strong>In our study, as in previous similar studies, we could not see the increased survival trend in pPCL which is observed in MM. New studies are needed for pPCL patients, which is likely to increase with the new diagnostic criteria, based on current agents and information in MM.</p>","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4274/tjh.galenos.2024.2024.0450","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: In this study, we aimed to obtain real-life data on the use of antimyeloma agents, which significantly increase overall survival (OS) in multiple myeloma (MM) patients, in primary plasma cell leukemia (pPCL) patients with a poor prognosis.
Materials and methods: Data from 53 patients who were diagnosed with pPCL between 2011-2020 and who used at least one proteasome inhibitor (PI) and/or immunomodulatory (IMID) agent were analyzed retrospectively. Depending on the year of pPCL diagnosis, 20% leukocytes or ≥2×109/L plasma cells in the peripheral blood were used.
Results: The median age of the patients was 58 years, and 23 (43.4%) patients were over 65 years of age. For first-line treatment, PI or IMID alone was used in 31 (58.5%) patients, and PI and IMID were used simultaneously in 15 (28.3%) patients. Additionally, 21 (39.6%) patients received transplantation, and 13 (24.5%) patients received maintenance treatment. The median progression-free survival was 4 (1-42) months. When patients whose primary disease was refractory to first-line therapy were excluded, the duration of treatment was 6.5 months. The median OS was 15 months, with a median follow-up of 15 months. Only 7 (13.2%) of the patients were alive at the last follow-up visit. Those with higher beta-2 microglobulin levels and ISS stage 3 and nontransplant patients receiving first-line treatment had shorter OS (p=0.005, p=0.02 and p=0.008, respectively). Otherwise, the concomitant use of PIs and IMIDs, the addition of chemotherapy to induction therapy, and the response to induction therapy or maintenance therapy did not affect OS.
Conclusion: In our study, as in previous similar studies, we could not see the increased survival trend in pPCL which is observed in MM. New studies are needed for pPCL patients, which is likely to increase with the new diagnostic criteria, based on current agents and information in MM.
期刊介绍：
The Turkish Journal of Hematology is published quarterly (March, June, September, and December) by the Turkish Society of Hematology. It is an independent, non-profit peer-reviewed international English-language periodical encompassing subjects relevant to hematology.
The Editorial Board of The Turkish Journal of Hematology adheres to the principles of the World Association of Medical Editors (WAME), International Council of Medical Journal Editors (ICMJE), Committee on Publication Ethics (COPE), Consolidated Standards of Reporting Trials (CONSORT) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).
The aim of The Turkish Journal of Hematology is to publish original hematological research of the highest scientific quality and clinical relevance. Additionally, educational material, reviews on basic developments, editorial short notes, images in hematology, and letters from hematology specialists and clinicians covering their experience and comments on hematology and related medical fields as well as social subjects are published. As of December 2015, The Turkish Journal of Hematology does not accept case reports. Important new findings or data about interesting hematological cases may be submitted as a brief report.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
